SANDOZ TOBRAMYCIN SOLUTION

Država: Kanada

Jezik: angleščina

Source: Health Canada

Kupite ga zdaj

Prenos Lastnosti izdelka (SPC)
27-05-2020

Aktivna sestavina:

TOBRAMYCIN

Dostopno od:

SANDOZ CANADA INCORPORATED

Koda artikla:

S01AA12

INN (mednarodno ime):

TOBRAMYCIN

Odmerek:

0.3%

Farmacevtska oblika:

SOLUTION

Sestava:

TOBRAMYCIN 0.3%

Pot uporabe:

OPHTHALMIC

Enote v paketu:

5ML

Tip zastaranja:

Prescription

Terapevtsko območje:

ANTIBACTERIALS

Povzetek izdelek:

Active ingredient group (AIG) number: 0110230005; AHFS:

Status dovoljenje:

APPROVED

Datum dovoljenje:

2005-10-04

Lastnosti izdelka

                                PRODUCT MONOGRAPH
Pr
SANDOZ TOBRAMYCIN
Tobramycin Ophthalmic Solution, USP
0.3% w/v
Antibacterial (ophthalmic)
Sandoz Canada Inc.
110 Rue de Lauzon
Boucherville, Quebec
J4B 1E6
Date of Revision
May 27, 2020
Submission Control No.: 238817
_Sandoz Tobramycin Product Monograph _
_ _
2
PRODUCT MONOGRAPH
Pr SANDOZ TOBRAMYCIN
Tobramycin Ophthalmic Solution, USP
ACTION AND CLINICAL PHARMACOLOGY
MECHANISM OF ACTION
Like other aminoglycosides, the bactericidal activity of tobramycin is
accomplished by specific
inhibition of normal protein synthesis in susceptible bacteria, but at
the present time, very little is
known about this action. It is thought that inhibition of synthesis is
due to an action on ribosomes
that, in turn, causes bacterial misreading of messenger RNA.
CLINICAL PHARMACOLOGY
Pharmacodynamics
Because the ocular concentrations of tobramycin achieved after topical
application are higher
than those which can be safely used in systemic therapy, standardized
susceptibility tests may
not be appropriate to predict the effectiveness of tobramycin.
The gram positive bacteria against which tobramycin solution is
clinically effective include the
coagulase-positive and coagulase-negative staphylococci, including
penicillin-resistant strains,
_Streptococcus pneumoniae_, other alpha-hemolytic streptococci, and
Group A beta-hemolytic and
non-hemolytic streptococci. The gram-negative bacteria against which
tobramycin solution has
been shown to have clinical effectiveness include most strains of
_Pseudomonas aeruginosa, _
_Escherichia coli, Klebsiella pneumonia, Enterobacter aerogenes,
Proteus mirabilis_ (indole
negative) and indole-positive _Proteus_ species, as well as
_Haemophilus _spp., _Moraxella_ spp., and
_Acinetobacter calcoacetius (Herellea vaginicoli)._ Bacterial
susceptibility studies show that many
microorganisms resistant to gentamicin retain susceptibility to
tobramycin. A significant
population resistant to tobramycin has not emerged; however, bacterial
resistance may develop
upon prolonged use.
_ _
_ _
Pha
                                
                                Preberite celoten dokument
                                
                            

Dokumenti v drugih jezikih

Lastnosti izdelka Lastnosti izdelka francoščina 27-05-2020

Opozorila o iskanju, povezana s tem izdelkom